30DEC

Libyan International Conference for Health Sciences

The First Libyan International Conference for Health Sciences (2024): Open University, Tripoli, Libya
Mediterranean Journal of Pharmacy and Pharmaceutical Sciences
https://app.periodikos.com.br/journal/medjpps/article/doi/10.5281/zenodo.7479770

Mediterranean Journal of Pharmacy and Pharmaceutical Sciences

Original article

Use of weight-reducing products among Libyans: Pharmacist intervention in obesity management

Nesren A. Jaaida, Hana A. Smeda, Rabab A. Alahrish

Downloads: 0
Views: 187

Abstract

Obesity is a complex and challenging global public health concern. It is a major disease involving excessive fat accumulation that may impair health. Obesity is dangerous and has been related to a range of long-term health issues that can impact adults and children. According to the World Health Organization, more than one billion people worldwide are obese as of March 2022. In the Libyan situation, the prevalence of obesity has increased among the public over the last decade. This cross-sectional survey-based study is conducted by using a self-structured questionnaire to evaluate the use of anti-obesity drugs and herbal products among Libyan people. Additionally, considered as an indirect method, pharmacist performance in obesity management was also evaluated. The investigators collected interview data from three different cities in the Northwest of Libya over a period of five months, in 2019. A total of 170 participants who use weight loss products were randomly selected to participate in the study after obtaining their verbal consent. The participants' experience with weight reduction agents revealed that more than half of the participants (52.3%) used herbal products while 32.0% of the participants have used drugs of chemical origin and 15.6% have used both (herbal and drugs). The majority of the participants (91.4%) used these products without medical consultation which in turn led to failure to lose and maintain weight with 74.2% gaining weight after stopping using these products. In conclusion, poor pharmacist intervention in obesity management was revealed where the majority of the participants reported that Libyan community pharmacists had not been offering weight management services, monitoring weight loss progress, or explaining the risks of being overweight or obese.

Keywords

Anti-obesity drugs, herbal product, obesity, pharmacist role, weight loss

References

  1. Rodriguez-Martinez A, Zhou B, Sophiea MK, Bentham J, Paciorek CJ, Iurilli ML, Boggia JG (2020) Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: a pooled analysis of 2181 population-based studies with 65 million participants. The Lancet. 396 (10261): 1511-1524. doi: 10.1016/S0140-6736(20)31859-6
  2. Pineda E, Sanchez-Romero LM, Brown M, Jaccard A, Jewell J, Galea G, Webber L, Breda J (2018) Forecasting future trends in obesity across Europe: the value of improving surveillance. Obesity Facts. 11 (5): 360-371. doi: 10.1159/000492115
  3. World Health Organization (WHO) Obesity and Overweight Fact Sheet No. 311. 2021.
  4. Billington CJ, Epstein LH, Goodwin NJ, Hill JO, Pi-Sunyer FX, Rolls BJ, Harrison B (2000) Overweight, obesity, and health risk. Archives of Internal Medicine. 160 (7): 898-904. doi: 10.1001/archinte.160.7.898
  5. Ministry of Health (MOH) Healthcare system in Libya. Factual report (2012) Retrieved from https://www.scribd.com/document/77356124/LibyaHealth-Report-2012. Accessed 20 Mar 2022.
  6. Elmehdawi RR, Elmajberi SJ, Behieh A, Elramli A (2008) Prevalence of gall bladder stones among type 2 diabetic patients in Benghazi Libya: a case-control study. Libyan Journal of Medicine. 4 (1): 27-30. doi: 10.4176/081122
  7. Helal F, Faraj A, Kablan N, Elfakhri M, Bukhatwa S (2018) Prevalence of vitamin d deficiency among overweight and obese Libyan females. Pharmacy and Pharmacology International Journal. 6 (6): 453-457. doi: 10.15406/ppij.2018.06.00217
  8. Lemamsha H, Randhawa G, Papadopoulos C (2019) Prevalence of overweight and obesity among Libyan men and women. BioMed Research International. 2019: 8531360. doi: 10.1155/2019/8531360
  9. Lemamsha HAA (2016) Exploring the risk and protective factors associated with obesity amongst Libyan adults (20-65 years). PhD Thesis. University of Bedfordshire. Luton, LU1 3JU, United Kingdom.
  10. Rodgers RJ, Tschöp MH, Wilding JP (2012) Anti-obesity drugs: past, present and future. Disease Models & Mechanisms. 5 (5): 621-626. doi: 10.1242/dmm.009621
  11. Fu C, Jiang Y, Guo J, Su Z (2016) Natural products with anti-obesity effects and different mechanisms of action. Journal of Agricultural and Food Chemistry. 64 (51): 9571-9585. doi: 10.1021/acs.jafc.6b04468
  12. National Institutes of Health (1998) Clinical guidelines for the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. Obesity Research. 6 (2): 51S-209S. PMID: 9813653.
  13. Kaukua J, Pekkarinen T, Sane T, Mustajoki P (2003) Health-related quality of life in obese outpatients losing weight with very-low-energy diet and behaviour modification: a 2-y follow-up study. International Journal of Obesity and Related Metabolic Disorders. 27 (9): 1072-1080. doi: 10.1038/sj.ijo.0802366
  14. Glazer G (2001) Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. Archives of Internal Medicine. 161 (15): 1814-1824. doi: 10.1001/archinte.161.15.1814
  15. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV (1997) Valvular heart disease associated with fenfluramine-phentermine. The New England Journal of Medicine. 337: 581-588. doi: 10.1056/NEJM199708283370901.
  16. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomized trials. Lancet. 370 (9600): 1706-1713. doi: 10.1016/S0140-6736(07)61721-8
  17. Kang JG, Park CY (2012) Anti-obesity drugs: a review about their effects and safety. Diabetes & Metabolism Journal. 36 (1): 13-25. doi: 10.4093/dmj.2012.36.1.13
  18. Williams DM, Nawaz A, Evans M (2020) Drug therapy in obesity: a review of current and emerging treatments. Diabetes Therapy. 1 (6): 1199-1216. doi: 10.1007/s13300-020-00816-y
  19. Padwal RS, Majumdar SR (2007) Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 369 (9555): 71-77. doi: 10.1016/S0140-6736(07)60033-6
  20. Müller TD, Blüher M, Tschöp MH, DiMarchi RD (2022) Anti-obesity drug discovery: advances and challenges. Nature Reviews Drug Discovery. 21: 201-223. doi: 10.1038/s41573-021-00337-8
  21. Singh G, Krauthamer M, Bjalme-Evans M (2022) Wegovy (semaglutide) (2022) A new weight loss drug for chronic weight management. Journal of Investigative Medicine. 70 (1): 5-13. doi: 10.1136/jim-2021-001952.
  22. Fu C, Jiang Y, Guo J, Su Z (2016) Natural products with anti-obesity effects and different mechanisms of action. Journal of Agriculture, Food and Chemistry. 64 (51): 9571-9585. doi: 10.1021/acs.jafc.6b04468
  23. Mohamed GA, Ibrahim SR, Elkhayat ES, El Dine RS (2014) Natural anti-obesity agents. Bulletin of Faculty of Pharmacy, Cairo University. 52 (2): 269-284. doi: 10.1016/j.bfopcu.2014.05.001
  24. Gray L, Chamberlain R, Morris C (2016) Basically you wait for an ‘in’: community pharmacist views on their role in weight management in New Zealand. Journal of Primary Health Care. 8 (4): 365-371. doi: 10.1071 /HC16026
  25. American Society of Health-System Pharmacists (2008) ASHP statement on the role of health-system pharmacists in public health. American Journal of Health-system Pharmacy. 65 (5): 462-467. doi: 10.2146/ajhp 070399
  26. KATZ MD (2001) ASHP therapeutic position statement on the safe use of pharmacotherapy for obesity management in adults. American Journal of Health-System Pharmacy. 58 (17): 1645-1655. doi: 10.1093/ajhp/ 58.17.1645
  27. Rosenthal M, Ward LM, Teng J, Haines S (2018) Weight management counselling among community pharmacists: a scoping review. International Journal of Pharmacy Practice. 26 (6): 475-484. doi: 10.1111/ ijpp.12453
  28. Jordan MA, Harmon J (2015) Pharmacist interventions for obesity: improving treatment adherence and patient outcomes. Integrated Pharmacy Research and Practice. 8; 4: 79-89. doi: 10.2147/IPRP.S72206
  29. Um IS, Armour C, Krass I, Gill T, Chaar BB (2013) Weight management in community pharmacy: what do the experts think? International Journal of Clinical Pharmacy. 35 (3): 447-54. doi: 10.1007/s11096-013-9761-4
  30. Hijazi MA, Shatila H, El-Lakany A, Al Rifai H, Aboul-Ela M, Naja F (2020) Role of community pharmacists in weight management: results of a national study in Lebanon. BMC Health Services Research. 20 (1): 386, 1-12. doi: 10.1186/s12913-020-05258-7
  31. AlMukdad S, Zaghloul N, Awaisu A, Mahfoud ZR, Kheir N, El Hajj MS (2021) Exploring the role of community pharmacists in obesity and weight management in Qatar: a mixed-methods study. Risk Management and Healthcare Policy. 14: 2771-2787. doi: 10.2147/RMHP.S309142
  32. Elhisadi TA (2022) Overall obesity and overweight, trend from 2016 to 2022 with a forecast for 3 years ahead in Estern Libya. International Journal of Research. 10 (6): 14-24. doi: 10.29121/granthaalayah.v10.i6.2022. 4599
  33. Martin CB, Herrick KA, Sarafrazi N, Ogden CL (2018) Attempts to lose weight among adults in the United States, 2013-2016. NCHS Data Brief. (313): 1-8. PMID: 30044214.
  34. Machado EC, Silveira MFD, Silveira VMFD (2012) Prevalence of weight-loss strategies and use of substances for weight-loss among adults: a population study. Cadernos de Saúde Pública. 28 (8): 1439-1449. doi: 10.1590 /s0102-311x2012000800003
  35. Liou TH, Wu CH, Chien HC, Lin WY, Lee WJ, Chou P (2007) Anti-obesity drug use before professional treatment in Taiwan. Asia Pacific Journal of Clinical Nutrition. 16 (3): 580-586. PMID: 17704041.
  36. Chopra S, Malhotra A, Ranjan P, Vikram NK, Singh N (2020) Lifestyle-related advice in the management of obesity: A step-wise approach. Journal of education and health promotion. (28) 9: 239. doi: 10.4103/jehp. jehp_216_20
  37. Tchang BG, Aras M, Kumar RB, Aronne LJ (2021) Pharmacologic treatment of overweight and obesity in adults. In: Feingold KR (Eds.), Endotext. Bookshelf ID: NBK279038. PMID: 25905267.
  38. Abd Malik MA, Ali MF, Muhammad NA (2019) The use of weight loss products among overweight and obese patients in Malaysia. Malaysian Journal of Medicine and Health Sciences. 15 (1): 23-30. ID: wpr-750672.
  39. Shehadeh MB, Suaifan G, Abu-Odeh A, Darwish R (2020) Complementary and alternative medicine use for weight management among females in Jordan: a community-based survey. Eastern Mediterranean Health Journal. 26 (4): 443-452. doi: 10.26719/emhj.19.098
  40. Kearns K, Dee A, Fitzgerald AP, Doherty E, Perry IJ (2014) Chronic disease burden associated with overweight and obesity in Ireland: the effects of a small BMI reduction at population level. BMC Public Health. 14: 143. doi: 10.1186/1471-2458-14-143
  41. Kivimäki M, Strandberg T, Pentti J, Nyberg ST, Frank P, Jokela M, Ferrie JE (2022) Body-mass index and risk of obesity-related complex multi-morbidity: an observational multi-cohort study. The Lancet. Diabetes & Endocrinology. 10 (4): 253-263. doi: 10.1016/S2213-8587(22)00033-X
  42. Eltobgi A (2009) Libya has the highest prevalence of diabetes mellitus type 2 in North Africa and in the Arab world. In Endocrine Abstracts. 19: P138.
  43. Zhou YH, Ma XQ, Wu C, Lu J, Zhang SS, Guo J, He J (2012) Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials. PloS one. 7 (6): e39062.
  44. Toplak H, Woodward E, Yumuk V, Oppert JM, Halford JC, Frühbeck G (2015) 2014 EASO position statement on the use of anti-obesity drugs. Obesity Facts. 8 (3): 166-174. doi: 10.1159/000430801
  45. Granara B, Laurent J (2017) Provider attitudes and practice patterns of obesity management with pharmacotherapy. Journal of American Association of Nurse Practitioners. 29 (9): 543-550. doi: 10.1002/2327-6924.12481
  46. Elsahoryi N, Al-Sayyed HF, McGrattan AM, Odeh MM, Hammad FJ (2021) Using of licensed and unlicensed anti-obesity medications among the university students. Nutrition and Food Processing. 4 (2): doi: 10.31579/2637-8914/043
  47. National Clinical Guideline Centre, UK (2014) Obesity: identification, assessment and management of overweight and obesity in children, young people and adults. National Institute for Health and Care Excellence (NICE). CG189.
  48. Sun NN, Wu TY, Chau CF (2016) Natural dietary and herbal products in anti-obesity treatment. Molecules. 21 (10): 1351. doi: 10.3390/molecules21101351
  49. Kang JG, Park CY (2012) Anti-obesity drugs: a review about their effects and safety. Diabetes & Metabolism Journal. 36 (1): 13-25. doi: 10.4093/dmj.2012.36.1.13.
  50. Egras AM, Hamilton WR, Lenz TL, Monaghan MS (2011) An evidence-based review of fat modifying supplemental weight loss products. Journal of Obesity. 2011: 297315. doi: 10.1155/2011/297315
  51. Bellikci-Koyu E, Şarer-Yürekli BP, Seckine S, Özdemir N, Buyuktuncer Z (2020) Use of herbal products for weight loss in Turkey. Progress in Nutrition. 22 (3): e2020008.
  52. Liu Y, Sun M, Yao H, Li, Y, Gao R (2017) Herbal medicine for the treatment of obesity: an overview of scientific evidence from 2007 to 2017. Evidence-based Complementary and Alternative Medicine: eCAM: 2017. 8943059. doi: 10.1155/2017/8943059
  53. Yerevanian A, Soukas AA (2019) Metformin: mechanisms in human obesity and weight loss. Current Obesity Reports. 8 (2): 156-164. doi: 10.1007/s13679-019-00335-3
  54. Awa A, Waheedi M (2012) Community pharmacist's role in obesity treatment in Kuwait: a cross-sectional study. BMC Public Health. 12: 863. doi: 10.1186/1471-2458-12-863
  55. Eades CE, Ferguson JS, O’Carroll RE (2011) Public health in community pharmacy: a systematic review of pharmacist and consumer views. BMC Public Health. 11: 582. doi.org/10.1186/1471-2458-11-582
  56. Katz MD (2001) ASHP therapeutic position statement on the safe use of pharmacotherapy for obesity management in adults. American Journal of Health-System Pharmacy. 58 (17): 1645-1655. doi: 10.1093/ajhp/58.17.1645
  57. Malone M (2004) Enhancing pharmacist involvement in weight management-time to get with the program. The Annals of Pharmacotherapy. 38 (11): 1961-1963. doi: 10.1345/aph.1E378
  58. AlMukdad S, Zaghloul N, Awaisu A, Mahfoud ZR, Kheir N, El Hajj MS(2021) Exploring the role of community pharmacists in obesity and weight management in Qatar: a mixed-methods study. Risk Management and Healthcare Policy. 14: 2771-2787. doi: 10.2147/RMHP.S309142
  59. Boardman HF, Avery AJ (2014) Effectiveness of a community pharmacy weight management programme. International Journal of Clinical Pharmacy. 36 (4): 800-806. doi: 10.1007/s11096-014-9964-3
  60. Ahrens RA, Hower M, Best AM (2003) Effects of weight reduction interventions by community pharmacists. Journal of the American Pharmacists Association. 43 (5): 583-589. doi: 10.1331/154434503322452210
  61. Newlands RS, Watson MC, Lee AJ (2011) The provision of current and future Healthy Weight Management (HWM) services from community pharmacies: a survey of community pharmacists' attitudes, practice and future possibilities. International Journal of Pharmacy Practice. 19 (2): 106-114. doi.org/10.1111/j.2042-7174. 2010.00080.x

Submitted date:
10/11/2022

Reviewed date:
11/24/2022

Accepted date:
01/02/2023

Publication date:
11/08/2024

672dcca6a95395718029fa26 medjpps Articles
Links & Downloads

Mediterr J Pharm Pharm Sci

Share this page
Page Sections